Antibodies, detection systems and accessories for immunohistology
Probes, kits and detection systems – visualizing DNA and RNA in tissue sections
Real-time PCR, Next Generation Sequencing (NGS) and DNA arrays – careful analysis, reliable detection
Semi-automated immunostaining systems – for maximum flexibility, highest staining quality and high throughput
Complete blocks, slide sets and individual tissue arrays – for routine and research
We are a Berlin-based company specializing in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in situ hybridization and molecular pathology.
Consistent high quality is a top priority. This is why development and manufacturing of our products are governed by a quality management system certified to ISO 9001:2015 and ISO 13485:2016. A majority of the Zytomed Systems products are CE labelled and are approved as reagents for in vitro purposes (CE/IVD). See the download section for our certificates.
At Zytomed Systems we will be also compliant with the IVDR requirements.
Learn moreEthically correct, respectful dealing with our business partners is of very high importance to Zytomed Systems GmbH and a matter of course. This includes all commercial, legal and interpersonal levels, concerns and aspects.
Learn moreThanks to our extensive network of distribution partners, you can order our products from anywhere in the world. The high degree of satisfaction of our customers speaks for itself. Our aim is to precisely tailor our products to your needs. Rely on our many years of experience, our quality, flexibility and excellent service.
Learn moreZytoMax is now the exclusive distributor of AmoyDx® products in Switzerland
We are delighted to inform you that due to the positive customer response, the molecular diagnostic products of our partner AmoyDx® are now available to our customers in Switzerland through ZytoMax Schweiz GmbH, a sister company of Zytomed Systems GmbH.
PRAME (PReferentially-expressed Antigen in MElanoma) was first described in a paper by Ikeda et al., through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. [1, 2]
As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).
The IVDR, in force since May 26, 2022, represents a turning point in the EU-wide harmonization of patient safety. At the same time, it places high demands on us as manufacturers and on you as a user of in vitro diagnostic medical devices to implement the new regulation. We would like to meet this challenge together with you for the benefit of your patients. It is important to us to certify our portfolio of diagnostic solutions in compliance with the IVDR in due time. Therefore, we would like to keep you informed about our progress with the implementation of the IVDR.
A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)